A carregar...
Trastuzumab Deruxtecan: Changing the Destiny of HER2 Expressing Solid Tumors
HER2 targeted therapies have significantly improved prognosis of HER2-positive breast and gastric cancer. HER2 overexpression and mutation is the pathogenic driver in non-small cell lung cancer (NSCLC) and colorectal cancer, however, to date, there are no approved HER2-targeted therapies with these...
Na minha lista:
| Publicado no: | Int J Mol Sci |
|---|---|
| Main Authors: | , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
MDPI
2021
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC8125530/ https://ncbi.nlm.nih.gov/pubmed/33946310 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3390/ijms22094774 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|